These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 27196891

  • 1. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
    Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.
    Int J Mol Sci; 2016 May 16; 17(5):. PubMed ID: 27196891
    [Abstract] [Full Text] [Related]

  • 2. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.
    Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.
    Mol Cancer Ther; 2012 Mar 16; 11(3):639-48. PubMed ID: 22238365
    [Abstract] [Full Text] [Related]

  • 3. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
    Yong KJ, Milenic DE, Baidoo KE, Kim YS, Brechbiel MW.
    Cancer Med; 2013 Oct 16; 2(5):646-53. PubMed ID: 24403230
    [Abstract] [Full Text] [Related]

  • 4. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
    Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.
    Int J Radiat Oncol Biol Phys; 2013 Mar 15; 85(4):1119-26. PubMed ID: 23200172
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
    Lindenblatt D, Terraneo N, Pellegrini G, Cohrs S, Spycher PR, Vukovic D, Béhé M, Schibli R, Grünberg J.
    BMC Cancer; 2018 Sep 25; 18(1):922. PubMed ID: 30253737
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
    Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.
    Br J Cancer; 2013 May 28; 108(10):2013-20. PubMed ID: 23632482
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics.
    Timmermand OV, Elgqvist J, Beattie KA, Örbom A, Larsson E, Eriksson SE, Thorek DLJ, Beattie BJ, Tran TA, Ulmert D, Strand SE.
    Theranostics; 2019 May 28; 9(8):2129-2142. PubMed ID: 31149033
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody.
    Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, Li F, Liu Z.
    Theranostics; 2021 May 28; 11(1):304-315. PubMed ID: 33391476
    [Abstract] [Full Text] [Related]

  • 16. Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease.
    Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE.
    Pharmaceuticals (Basel); 2011 Dec 22; 5(1):1-15. PubMed ID: 22229017
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T, Bötticher B, Arndt MA, Mier W, Sauter M, Exner E, Keller A, Krämer S, Leotta K, Wischnjow A, Grosse-Hovest L, Strumberg D, Jäger D, Gröne HJ, Haberkorn U, Brem G, Krauss J.
    Cancer Lett; 2016 Oct 28; 381(2):296-304. PubMed ID: 27524505
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
    van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Lütje S, McBride WJ, Oyen WJ, Boerman OC.
    Cancer Biother Radiopharm; 2014 Oct 28; 29(8):323-9. PubMed ID: 25226447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.